Quick Answer
CATALYST PHARMACEUTICALS, INC. reported Revenue From Contract With Customer Excluding Assessed Tax of $588.99 million for the year ending 2025.
- CATALYST PHARMACEUTICALS, INC. showed an increase of +19.8% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from CATALYST PHARMACEUTICALS, INC.'s annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $12.45 million | Q2 2019: $28.84 million | Q3 2019: $30.90 million | Q4 2019: $30.12 million | Q1 2020: $29.14 million | Q2 2020: $29.61 million | Q3 2020: $29.32 million | Q1 2021: $30.21 million | Q2 2021: $36.37 million | Q3 2021: $35.95 million | Q1 2022: $43.09 million | Q2 2022: $53.11 million | Q3 2022: $57.24 million | Q1 2023: $85.37 million | Q2 2023: $99.58 million | Q3 2023: $102.69 million | Q1 2024: $98.51 million | Q2 2024: $122.71 million | Q3 2024: $128.70 million | Q1 2025: $141.42 million | Q2 2025: $146.56 million | Q3 2025: $148.39 million.
- Over the full 7 years of available data (2019 to 2025), CATALYST PHARMACEUTICALS, INC.'s Revenue From Contract With Customer Excluding Assessed Tax has grown by 475.7%.
- Historical annual values: Fiscal year 2025: $588.99 million | Fiscal year 2024: $491.73 million | Fiscal year 2023: $398.20 million | Fiscal year 2022: $214.20 million | Fiscal year 2021: $140.83 million | Fiscal year 2020: $119.07 million | Fiscal year 2019: $102.31 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: